Chelsea Pinnix is an Associate Professor in the Department of Radiation Oncology at MD Anderson Cancer Center where she specializes in the treatment of patients with hematologic malignancies. Her research is focused on the maximization of the therapeutic ratio for patients with hematologic malignancies through the utilization of radiation therapy. She is the principal investigator of clinical studies aimed at decreasing normal tissue toxicity from radiation through the use of advanced technology to reduce radiation exposure, utilization of smaller field sizes or reduced RT doses. She is also focused on the identification of improved treatment strategies that incorporate radiation combined with immune based therapies in the management of aggressive and refractory lymphomas.
In addition to her commitment to patient care and clinical research she is also passionate about resident education. She is presently the Program Director of the Radiation Oncology Residency Program at MD Anderson Cancer Center. She is a Steering Committee member of the International Lymphoma Radiation Oncology Group (ILROG) as well as the Radiation Chair for the Myeloma Committee of SWOG. She currently serves on the ASTRO Annual Meeting Scientific Committee as Vice Chair for the Hematologic Malignancies Section, is an oral board examiner for the American Board of Radiology (ABR), is a contributor to the ACR Radiation Oncology In-Training Exam for the Lymphoma/Leukemia Section and is the Chair of the Scientific Program for the American Radium Society (ARS).